Insider Trading History of Vertex Pharmaceuticals Inc / Ma

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Vertex Pharmaceuticals Inc / Ma since 2006. The trader's CIK number is 875320. At the time of the last reporting, Vertex Pharmaceuticals Inc / Ma was the 10% Owner of Crispr Therapeutics Ag. (stock ticker symbol CRSP). Also see all insider trading activities at Crispr Therapeutics Ag.

Note that in the past VERTEX PHARMACEUTICALS INC / MA also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Altus Pharmaceuticals Inc. (ALTU) by Vertex Pharmaceuticals Inc / Ma

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2006 ALTU 0 $0 817,749 $11,677,455 0 $0

Yearly summary of insider trading at Crispr Therapeutics Ag (CRSP) by Vertex Pharmaceuticals Inc / Ma

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2018 CRSP 130,940 $3,126,382 0 $0 0 $0


Insider trading activities at 2 companies by Vertex Pharmaceuticals Inc / Ma:

1. Altus Pharmaceuticals Inc. (ALTU)

2. Crispr Therapeutics Ag (CRSP)

Table 1. Insider trading of Altus Pharmaceuticals Inc. (ALTU) by Vertex Pharmaceuticals Inc / Ma

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2006-07-31 ALTU Sale 817,749 14.28 11,677,455

Table 2. Insider trading of Crispr Therapeutics Ag (CRSP) by Vertex Pharmaceuticals Inc / Ma

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2018-12-27 CRSP Buy 27,461 24.95 685,124
2018-12-26 CRSP Buy 12,737 24.89 317,074
2018-12-24 CRSP Buy 68,000 23.69 1,610,716
2018-12-21 CRSP Buy 22,742 22.58 513,468

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Vertex Pharmaceuticals Inc / Ma (10% Owner of Crispr Therapeutics Ag at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.